BAY Y 1015

Drug Profile

BAY Y 1015

Latest Information Update: 12 Sep 2000

Price : $50

At a glance

  • Originator Bayer
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Inflammatory bowel diseases; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 12 Sep 2000 No-Development-Reported for Asthma in Germany (Unknown route)
  • 12 Sep 2000 No-Development-Reported for Inflammatory bowel disease in USA (Unknown route)
  • 12 Sep 2000 No-Development-Reported for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top